Lack of MRE11-RAD50-NBS1 (MRN) complex detection occurs frequently in low-grade epithelial ovarian cancer

Simone Brandt 1, Eleftherios P. Samartzis 2, Anne-Katrin Zimmermann 3, Daniel Fink 2, Holger Moch 1, Aurelia Noske 1* and Konstantin J. Dedes 2†

Abstract

Background: BRCA1/2-deficient ovarian carcinomas are recognized as target for Poly (ADP-ribose) polymerase (PARP) inhibitors. BRCA1 and BRCA2 proteins are involved in homologous recombination repair of double-strand DNA breaks. The relevance of other homologous recombination repair proteins, e.g. MRE11, RAD50, NBS1 (MRN complex) in ovarian carcinomas is unclear. The objective of this study was to investigate the prevalence of lack of MRE11, RAD50, NBS1 protein detection in epithelial ovarian cancer (EOC).

Methods: A tissue microarray (TMA) with 134 EOC was immunohistochemically evaluated for MRE11, RAD50 and NBS1. Data was analysed for associations with clinicopathological parameters, histological subtype, patient overall survival and mismatch repair (MMR) protein status. Sensitivity towards the PARP inhibitor BMN673 was tested in two ovarian cancer cell lines (TOV-21 and OVTOKO) using colony formation assays.

Results: Lack of MRN complex protein detection was seen in 41% (55/134) of EOC and was more frequent in low-grade (57.6%; 19/33) than in high-grade EOC (18.8%; 36/101; n=134; p=0.04). There was an association with the ovarian carcinoma subtype (60.3%; 35/58 lack of detection in type I versus 26.3%; 20/76 in type II; n=134; p<0.001) as well as undetectable DNA mismatch repair proteins MLH1 and MSH2 (89.3%; 25/28; n=131; p<0.001). MRE11 knockdown led to moderately increased sensitivity towards the PARP inhibitor BMN673 in one ovarian carcinoma cell line in vitro.

Conclusions: Frequent lack of MRE11, RAD50, NBS1 protein detection in type I human ovarian carcinomas is observed in EOC and our data suggests further investigation regarding sensitivity to PARP-inhibition in tumours lacking MRE11 expression.

Keywords: Ovarian cancer, MRN complex, PARP inhibitor

Background

Epithelial ovarian cancer (EOC) represents about 30% of gynaecological cancers and is the leading cause of gynaecological cancer death in the Western world [1]. Patients with EOC often present in an advanced disease stage [2]. The current treatment strategy is surgery followed by platinum-based chemotherapy [3]. Due to resistance to chemotherapy and recurrence of the disease, long term survival of ovarian carcinoma patients remains poor.

Histologically, EOC is a heterogeneous group including low- and high-grade serous cancer, mucinous, endometrioid and clear cell cancer. Germline BRCA1 and BRCA2 mutations account for about 10–15% of ovarian cancers and are mainly found in high-grade serous and endometrioid ovarian carcinomas [4, 5]. BRCA1 and BRCA2 are critical proteins in the process of homologous recombination repair (HR) of double-strand DNA breaks. In addition to BRCA1 and BRCA2, many other proteins are involved in the HR repair process of double-strand DNA breaks and are implicated in hereditary breast and ovarian
cancer susceptibility. Such genes include ATM, CHEK2, BARD1, BRIP1, MRE11, RAD50, NBS1, RAD51C, RAD51D and PALB2 [6]. In the initial stages of HR, a double-strand DNA break is recognized by ATM and ATR, kinases that phosphorylate downstream targets including p53 and BRCA1. BRCA1 acts as a scaffold that organizes the remaining proteins to the site of repair. In a second phase of HR repair of double-strand DNA breaks, the MRN complex, which consists of MRE11, RAD50 and NBS1, resects the DNA to form 3’ overhangs. This is followed by loading of RAD51 onto RPA-coated DNA under the influence of BRCA2 [7–9].

The MRN complex can be inactivated or impaired by mutations or epigenetic silencing occurring in one of its three components. Homozygous MRE11 and NBS1 germ-line mutations that cause a lethal phenotype in mice are rarely encountered in humans and lead to an Ataxia telangiecstasy-like disorder (ATLD) and Nijmegen breakage syndrome (NBS), respectively. Heterozygous germ-line mutations of MRN complex genes may be associated with breast and ovarian cancer susceptibility [10–13]. In recent years, HR repair of double-strand DNA breaks has become a target for cancer therapy because BRCA1/2-deficient cancers are recognized as a target for a class of drugs known as PARP (poly (ADP-ribose) polymerase) inhibitors [14, 15]. PARP inhibitors work through direct blocking of PARP enzymatic activity. PARP represents a family of enzymes involved in base excision repair (BER), a key pathway in the repair of single-strand DNA breaks. Three excision repair pathways exist to repair single-stranded DNA damage: Nucleotide excision repair (NER), base excision repair (BER) and DNA mismatch repair (MMR). Loss of DNA MMR proteins is seen in hereditary non-polyposis colorectal cancer (HNPPC), but also in ovarian carcinomas [7, 8, 16].

In the situation of PARP inhibition, single-strand DNA breaks are converted into double-strand DNA breaks through collapse of the replication fork. In BRCA-deficient tumors, homologous recombination repair is not functional. Therefore, the deficiency of both, HR repair of double-strand DNA breaks and single-strand DNA damage repair due to PARP inhibition leads to death of tumor cells. The term synthetic lethality means that deficiency of PARP or BRCA alone has no impact, but a deficiency in both leads to a lethal effect in tumor cells because the tumor cells are directed towards error-prone repair and consecutive cell death [6].

In the last years, PARP inhibitors have shown promising results among BRCA1/2 mutation carriers, among them several completed trials for PARP inhibition in BRCA1 and BRCA2-mutated patients with EOC [14, 17, 18]. A completed study in patients with relapsed high-grade serous ovarian cancer showed improved progression free survival among patients with platinum-sensitive relapsed tumors, but no overall survival improvement [19, 20].

In sporadic tumors, genes in DNA repair may also be altered due to somatic mutations or epigenetic alterations. In high-grade serous EOC, up to 50% harbor disruption of HR by mutations or epigenetic silencing of BRCA1/2, RAD51 and others [21] and up to 29% of EOC harbor defects of MMR [22, 23]. The Cancer Genome Atlas (TCGA) suggests that deficiency of either BRCA1 or BRCA2 occurs through somatic mutation (3% BRCA1 or BRCA2) or through epigenetic silencing of BRCA1 (11%) in sporadic EOC. Other genetic changes affecting HR repair include amplification of EMSY (8%), deletion/mutation of PTEN (7%), hypermethylation of RAD51C (3%), mutation of ATM or ATR (2%) or mutation of other HR genes (5%). These tumors have the phenotype of “BRCAness” and are predicted to act like BRCA-deficient tumors despite wild-type germline BRCA1 and BRCA2 genes. Such BRCA-deficient ovarian cancers show improved survival, due to a better response to platinum chemotherapy [6].

In vitro experiments have demonstrated that deficiency in HR by mutations in MRE11-RAD50-NBS1 (MRN) complex may sensitize cancer cells to treatment with PARP inhibitors [24–26] and might therefore serve as a predictive biomarker of PARP inhibitor therapy. There is some growing body of evidence that patients with other mutations than BRCA1/2 may also benefit from PARP inhibitors [15, 27–29].

So far, the expression pattern of the MRN complex in gynaecological carcinomas is not well elucidated. Due to the key role of the MRN complex in HR of double-strand DNA breaks, the aim of our study was to evaluate the prevalence of absent protein staining of the MRN complex (MRE11, RAD50 and NBS1) in EOC.

Methods

Tissue microarray

Tissue microarray (TMA) with formalin-fixed and paraffin embedded ovarian carcinomas was previously constructed [30]. The study was approved by the local scientific ethics committee (KEK-ZH-Nr: StV 27–2009) and the need for individual consent has been waived by the ethics committee. 144 cancer samples of the archive of the Institute of Surgical Pathology, University Hospital Zurich (Switzerland) were included in this study. Clinical and pathological characteristics were taken from the clinical databases and pathology records. Routine hematoxylin and eosin sections were performed for histopathological evaluation. The stage of tumors was assessed according to the International Federation of Gynaecology and Obstetrics (FIGO) and TNM staging system. Histological subtype and tumor grade was defined according to the WHO classification 2014 [31]. Low-grade serous
carcinomas were excluded due to low sample number. The histological grade was classified as low-grade (including well to moderately differentiated endometrioid and mucinous carcinomas) and high-grade (combining high-grade serous, clear cell and poorly differentiated endometrioid cancer). In addition, we classified all EOC according to the Kurman model with two types of progression pathways as type I ovarian carcinomas (low-grade serous cancer, mucinous, endometrioid and clear cell cancer) and type II ovarian carcinomas (especially high-grade serous cancer) [32]. Follow-up data is known from all patients. The mean follow-up time was 56.6 months (range 0.13–201.2 months). Data on adjuvant chemotherapy were known for all patients. Adjuvant chemotherapy was administered in 102 women and was mainly platinum based (68%). The remaining 42 patients (29.2%) did not receive any chemotherapy after surgery. Resistance to chemotherapy is defined as disease progression or recurrence within 6 months after end of therapy / within a 6 month therapy-free interval. Sensitive status was defined as a therapy-free interval of at least 6 months without evidence of tumor progression or recurrence. In our cohort, 50 (34.7%) cases were classified as sensitive (relapse >6 months) and 32 (22.2%) as resistant (relapse <6 months). In 20 (13.9%) cases the response status could not be determined.

Baseline characteristics of patients with ovarian cancer are summarized in Table 1.

### Immunohistochemistry

After antigen retrieval, the slides were incubated with the following antibodies: MRE11 (clone 31H4, cell signalling, no.4847, 1:500), RAD50 (13B3/2C6, Abcam limited, no. ab89, 1:500), NBS1-p95 (cell signalling, no. 3002, 1:50). After incubation for 1 hour at room temperature, the staining of MRE11, RAD50 and NBS1 was further conducted with the Ventana Benchmark automated system (Ventana Medical Systems, USA) using Ventana reagents as well as the UltraMap™ DAB detection kit as described previously [24]. Analysis of all stainings was independently performed by two pathologists (SB, AN). Nuclear immunoreactivity of MRE11, RAD50 and NBS1 was scored as: negative (0), weak (1), moderate (2) and strong (3). Stromal cells showing nuclear staining were used as a positive control.

The antibodies against the mismatch repair proteins MLH1 (G168-15, PharMingen, Becton Dickinson, 1:100) and MSH2 (25D12, Novocastra Lab. Ltd, 1:100) were incubated for 30 min and the staining procedure was carried out with the automated Leica BOND system using the Bond Polymer Refine Detection Kit (Leica Biosystems) as described previously [24]. The protein detection of the mismatch repair genes was considered positive when nuclear staining was evident. Stromal and inflammatory cells showing nuclear staining served as a positive control.

### Cancer cell lines and growth conditions

The ovarian clear cell cancer (OCCC) cell lines TOV-21 and OVTOKO were grown in RPMI supplemented with 10% (v/v) fetal bovine serum and 1% (v/v) antibiotic-antimycotic additive and incubated at 37 °C in a humidified atmosphere at 5% CO2. The serous ovarian cancer cell line OV-90 was purchased at ATCC and grown in a 1:1 mixture of MCDB 105 medium containing a final concentration of 1.5 g/L sodium bicarbonate and Medium 199 containing a final concentration of 2.2 g/L sodium bicarbonate supplemented with 15% (v/v) fetal bovine serum and 1% (v/v) antibiotic-antimycotic additive and incubated at 37 °C in a humidified atmosphere at 5% CO2. All cell culture components were purchased from Gibco (LifeTechnologies).

### siRNA and transfections

MRE11 knockdowns were performed simultaneously with a pool of three different siRNA sequences (Microsynth, Switzerland) using RNAimax (Gibco by LifeTechnologies) according to the manufacturer’s instruction, each performed as two independent experiments. The target sequences (sense) were: GCUAAUGACUCUGAUATT, GAGCAUAACUCCAUAAGUATT and GAUGCCAUUG AGGAAUUGATT [24]. The controls were transfected with siRNA against luciferase (sense): CGUACGCGGA AUACUUCGATT. Cells were seeded 24 h after siRNA
transfection and the treatment with the PARP inhibitor BMN673 was initiated after 48 h [23].

**Colonies formation assays**
The PARP inhibitor BMN673 was a gift from Biomarin Pharmaceuticals, USA. Survival assays were carried out as previously described [33, 34]. In brief, the previously transfected cells were seeded in six-well plates in triplicates at a concentration of 1000 cells per well. The PARP inhibitor treatment was started after 24 h and cells were continuously exposed to the PARP inhibitor (10–11 to 10–6 M) and the medium was replaced every 3 to 5 days. The controls were treated with the vehicle substance (DMSO). Cells cultures were grown until the controls reached 80–90% confluence after 10 to 15 days and then fixed with TCA 10%. After fixation, cell cultures were stained with sulforhodamine B (SRB) (Sigma) and a colorimetric assay was performed as described previously [33].

**Mutation analysis**
The EOC cohort was previously characterized for KRAS and TP53 gene mutations [35]. We analyzed KRAS exon 2 and 3 and TP53 exon 5–8 by pyrosequencing using the GS Junior 454 platform.

**Immunoblotting**
Protein extraction was performed with a SDS lysis buffer. The primary antibodies used for western blotting against MRE11 (D151 (sheep), gift from Steve Jackson, Cambridge) and beta-actin (mouse monoclonal antibody, Sigma). The incubation was followed by an HRP-conjugated secondary antibody (anti-sheep HRP from Santa-Cruz and anti-mouse HRP from Sigma), then followed by chemiluminescent detection (FemtoGlow Western, Michigan Diagnostics, Cat # FWPS02-500). Images were acquired electronically using a Fusion FX® (Vilber Lourmat, Marne-la-Vallée, France) detecting system.

**Statistical analysis**
The statistical evaluation was performed with the SPSS software Version 21.0 (SPSS Inc., Chicago, IL, USA). The scoring data of MRE11, RAD50 and NBS1 were dichotomized into “negative” (no detection) and “positive” (weak to strong detection). The statistical significance of the association between these markers, the mismatch repair protein detection as well as clinicopathological parameters was assessed by Chi² test and Fisher’s exact test. In addition, Spearman’s correlation was used to evaluate an association between MRE11, RAD50, NBS1 and mismatch repair proteins. The probability of overall survival as a function of time was determined by the Kaplan-Meier method. Differences in survival curves were compared by the log rank test. Sensitivity curves were calculated in GraphPad Prism Version 6 (GraphPad Software Inc., La Jolla, USA) and statistical differences between IC50 values were assessed using F-tests. The plotted values represent the mean surviving fraction and the error bars represent the standard error of mean (SEM) for two independent knockdown experiments, with each experiment performed in triplicates. P-values < 0.05 were considered as significant.

**Results**

**MRN complex detection and clinicopathological parameters**
Immunohistochemical analysis of MRE11, RAD50 and NBS1 was successful in a maximum of 134 carcinomas. Staining results for some TMA spots were not obtained due to loss of tumor tissue during technical processing. MRE11, RAD50 and NBS1 immunohistochemical reactions showed only nuclear staining. The immunohistochemical data are summarized in Table 2. Representative images are shown in Fig. 1. Non-neoplastic stromal cells showed sustained staining of all three markers. For further statistical analysis, only completely absent staining (score 0) was considered as negative and any detectable staining (weak to strong) was considered positive.

Statistically, we found a significant positive association between MRE11 and RAD50 as well as NBS1 detection (Table 3, p < 0.0001, Fisher’s Exact test). Further, a significant positive association was found between RAD50 and NBS1 (p < 0.0001, Fisher’s Exact test). Due to this association, we defined a combined loss of MRN complex proteins as loss of either of the proteins MRE11, RAD50 or NBS1.

We evaluated the association of the MRN complex (combined detection of all three proteins) with clinicopathological factors. Lack of MRN complex detection was significantly associated with histological subtype and differentiation grade. According to the Kurman progression
pathway model [32], lack of MRN protein detection occurred significantly more frequently in type I tumors (p < 0.001, Table 4).

MRE11, RAD50 and NBS1 Detection and Mismatch Repair Protein Detection
We investigated mismatch repair protein expression by immunohistochemistry in a maximum of 133 ovarian carcinomas. Any lack of detection of one of the proteins MSH2 or MLH1 was integrated in a MMR deficiency state. MMR deficiency was observed in 21% of all EOC. All three MSH2 negative cases were also negative for MLH1.

MRE11, RAD50 and NBS1 were significantly associated with mismatch repair protein detection (p < 0.05, Fisher’s Exact test). The correlation among all proteins was confirmed in a bivariate (nonparametric) analysis (MRE11 and RAD50 (correlation coefficient 0.451; n = 135; p-value <0.001); MRE11 and NBS1 (correlation coefficient 0.741; n = 135; p-value <0.001); RAD50 and NBS1 (correlation coefficient 0.377; n = 134; p-value <0.001)), calculated with Spearman’s rho.

MRN complex overall survival and response to chemotherapy
In univariate Kaplan-Meier analysis, FIGO stage, histologic subtype, grading and patient age were significant prognostic factors for overall survival (log rank, p-value <0.05 for each parameter). Detection of MRE11 (log rank, p = 0.28), RAD50 (log rank, p = 0.32), NBS1 (log rank, p = 0.9), MMR status (log rank, p = 0.79) was not associated with

Table 3 Association of the MRN complex proteins

|                | MRE11 negative n (%) | MRE11 positive n (%) | p-value |
|----------------|-----------------------|----------------------|---------|
| **RAD50 (n = 135)** |                       |                      |         |
| Negative       | 14 (10.4)             | 0 (0)                | <0.001* |
| Positive       | 35 (25.9)             | 86 (63.7)            |         |
| **NBS1 (n = 135)** |                       |                      |         |
| Negative       | 39 (28.9)             | 6 (4.4)              |         |
| Positive       | 10 (7.4)              | 80 (59.3)            | <0.001* |
| **MMR (n = 133)** |                       |                      |         |
| Negative       | 25 (18.8)             | 3 (2.3)              |         |
| Positive       | 22 (16.5)             | 83 (62.4)            | <0.001* |

*Fisher’s Exact test

Table 4 Association of MRN complex with clinicopathological factors and MMR status

| Variable                  | n   | MRN complex negative n (%) | p-value |
|---------------------------|-----|----------------------------|---------|
| FIGO stage                |     |                            |         |
| Early (I & II)            | 40  | 20 (50)                    | 0.017*  |
| Late (III & IV)           | 88  | 32 (36.4)                  |         |
| Histologic subtype        |     |                            |         |
| High-grade serous         | 67  | 17 (25.4)                  | 0.001b  |
| Mucinous                  | 14  | 9 (64.3)                   |         |
| Clear cell                | 25  | 16 (64.0)                  |         |
| Endometrioid              | 28  | 13 (46.4)                  |         |
| Grade                     |     |                            |         |
| Low-grade                 | 33  | 19 (57.6)                  | 0.04a   |
| High-grade                | 101 | 36 (35.6)                  |         |
| Kurman model              |     |                            |         |
| Type I                    | 58  | 35 (60.3)                  | 0.0001a |
| Type II                   | 76  | 20 (26.3)                  |         |
| MMR status                |     |                            |         |
| Negative                  | 28  | 25 (89.3)                  | <0.0001a|
| Positive                  | 103 | 27 (26.2)                  |         |
| KRAS status               |     |                            |         |
| wt                        | 114 | 43 (37.7)                  | 0.082a  |
| Mutation                  | 14  | 9 (64.3)                   |         |
| TP53 status               |     |                            |         |
| wt                        | 58  | 24 (41.4)                  | 0.9a    |
| Mutation                  | 70  | 28 (40.0)                  |         |

*Fisher’s Exact test; bchi-square Pearson
overall survival. NBS1 detection tended to be associated with a platinum-sensitive status \((p = 0.058, \text{ Fisher's Exact Test})\). MRE11 and RAD50 did not show any association with response to chemotherapy.

**Association of the MRN complex with KRAS and TP53 mutation status**

Since KRAS and TP53 gene mutations are important in ovarian carcinogenesis, we evaluated whether an association can be found with mutation status, which was recently described in our cohort [35]. Ovarian carcinomas with KRAS mutation showed frequent lack of NBS1 detection \((p = 0.013, \text{ Fisher's exact test})\) and a trend for MRE11 negativity \((p = 0.08, \text{ Fisher's exact test})\). No association with TP53 mutation status was observed (Table 4).

**Knockdown of MRE11 sensitizes OCCC cells towards the PARP inhibitor BMN673 in vitro**

We assessed PARP inhibitor sensitivity in the MRE11-depleted cells by colony formation in triplicates. The efficiency of the siRNA knockdowns was verified by western blots as described before [21]. Upon depletion of MRE11, we observed a moderate decrease in cell viability in the presence of the PARP inhibitor BMN673 (Fig. 2). The IC50 values for BMN673 were 4.1 e–10 M in the MRE11-depleted TOV21 and 9.3 e–10 M in the controls \((p = 0.0005)\). In OVTOKO IC50 was 5.4 e–9 M in the MRE11-depleted cell line and 7.5 e–9 M in the controls \((p = 0.2)\).

**Discussion**

In this study, immunohistochemical analysis showed a frequent lack of detection of the MRN complex (MRE11, RAD50, NBS1) in EOC. With our immunohistochemical approach, we provide evidence for lack of protein detection of RAD50 in 10% (14/136), NBS1 in 33% (45/135) and MRE11 in 36% (49/136) of EOC. In a combined MRN score, 44% (55/134) of all EOC have at least one undetectable protein of the three MRN proteins. Our finding is consistent with results of a previous study that demonstrated a reduced detection of MRE11, RAD50, and NBS1 in cancer tissue by immunohistochemistry as compared to the control group of healthy ovaries and serous cystadenomas [36]. Recently, we investigated these proteins in endometrial cancer (EC) and observed a lack of detection in up to 30% of the cases [9].

There are different mechanisms of MRN protein deficiency. Mutations of genes of the MRN complex have been described in other cancers, including colorectal and endometrial cancer. For MRE11, mutations of the intronic poly (T) sequence between exons 4 and 5 are frequent events in MSI-positive colorectal and endometrial cancers [37, 38]. However, in a recent next-generation sequencing study by exome-wide analysis in ovarian cancer, the prevalence of MRN gene mutations is uncommon. MRE11 accounted for only 3% of somatic mutations of HR genes and NBS1 only for 1% of germline mutations, respectively [6]. Therefore, different mechanisms which lead to undetectable MRN proteins might be suggested, such as epigenetic silencing [39] and post-transcriptional regulation by miRNA [40].

We observed an association between lack of MRN detection and MMR deficiency, assessed by MLH1 and MSH2 immunohistochemistry. MLH1 functions as a nuclear-encoded protein in mitochondrial mismatch repair, MSH2 functions in nuclear mismatch repair. Germline mutations in MSH2 and MLH1 account for the majority of HNPCC families implicating mismatch repair as etiology [41]. We have previously shown that nuclear immunoreactivity for MLH1, MSH2 or MSH6 proteins is retained in all microsatellite stable ovarian carcinomas [22]. 65% of microsatellite unstable ovarian carcinomas displayed some detectable MLH1, MSH2 and MSH6, but a complete lack of MLH1, MSH2 or MSH6 detection was only seen in carcinomas with microsatellite instability [22, 42]. Therefore, our data indicate that lack of MRN detection can be associated with MMR deficiency in EOC. This is consistent with recent studies, showing that somatic mutations in MRE11 are frequently detected in MSI-positive colorectal and endometrial cancers [6, 37, 38, 43]. Previously, we have observed that lack of MRN protein detection was also associated with undetectable MMR proteins in endometrial cancer [24]. This suggests that the components of the MRN complex might be a common target of MSI and might contribute to tumor progression.

In vitro experiments demonstrate that deficiency in HR by mutations in the MRE11-RAD50-NBS1 (MRN) complex may sensitize cancer cells to treatment with PARP inhibitors [26, 29, 44, 45]. We observed an increased sensitivity towards the PARP inhibitor BMN673 in the OCCC cell line TOV21 after knockdown of MRE11. A similar tendency was observed in the second OCCC cell line OVTOKO. The OCCC cell lines were chosen because of the higher rate of undetectable MRN proteins among the Type I ovarian cancer group in our TMA. The increase in PARP inhibitor sensitivity after MRE11 knockdown is in line with previous observations made in endometrial cancer cell lines [24]. However, the effect was less pronounced in the OCCC cell lines which may be caused by factors like reduced transfection efficiency in these cell lines.

Our data suggest that loss of MRE11 in ovarian and endometrial cancer may predict sensitivity to PARP inhibitor in vitro and supports further investigation on MRE11 as a predictive biomarker for PARP inhibitor treatment [24]. However, the deficiency of several proteins other than BRCA1/2 or the MRN complex involved in HR, such as
RAD51, RAD54, DSS1, RPA1, ATR, ATM, CHK1, CHK2, FANCD2, FANCA or FANCC might also be sensitive to treatment with PARP inhibitors [6, 46].

In this study, MRN complex detection was not associated with response to chemotherapy or overall survival, which is consistent with previous studies in EOC [36] or endometrial cancer [24]. Although, loss of MRN complex is associated with impaired HR DNA repair [47], which renders cancer cells exquisitely sensitive to platinum-salts. This was recently shown in a large series of 390 ovarian cancer samples, where defects in HR were predictive for overall survival and primary platinum sensitivity [6]. The impact of MMR deficiency on chemotherapy resistance in EOC is controversial and investigated to a lesser extent [23]. The complex role and interaction of the MRN complex and MMR status has to be further evaluated.

Our data suggest that lack of MRN complex detection is more frequent in nonserous histologies (type I EOC) than in high-grade serous EOC [32]. Undetectable MRN protein was only weakly associated with low differentiation grade (p < 0.05). We classified the histological grade as low-grade (including well to moderately differentiated endometrioid and mucinous carcinomas) and high-grade (combining high-grade serous, clear cell and poorly differentiated endometrioid cancer). Importantly, undetectable MRN complex showed stronger association with the Kurman model of two progression pathways: Type I low-grade ovarian carcinomas (low-grade serous cancer, mucinous, endometrioid and clear cell cancer), which are characterized by mutations in genes like KRAS, BRAF, ERBB2, PTEN, PI3CA, CTNNB1, ARID1A and PPP2R1A, in the absence of TP53 mutations. These type I EOC more often showed an undetectable MRN complex than the aggressive type II high-grade ovarian carcinomas (especially high-grade serous cancer) with a high frequency of TP53 mutations [32]. Type II EOC typically occurs in patients with germline BRCA1 and BRCA2 mutations, which are treated with PARP inhibitors. Our data suggest that patients with type I EOC may also benefit from PARP inhibitors.

Finally, we searched for an association between gene mutations of TP53 and KRAS and the protein detection of the MRN complex. Lack of NBS1 protein detection was associated with KRAS mutation, presumably due to the strong association between type I EOC and lack of MRN protein detection. In a previous study, a relation of NBS1 to the RAS/RAF/MER/ERK cascade and its influence in cell proliferation was shown [34]. Thus, NBS1
is not only involved in DNA repair but also in other cellular processes such as signalling and proliferation. It was further reported that p53 mutants interact with the MRN complex [48]. However, in our cohort we did not observe an association between TPS3 mutated ovarian carcinomas and MRN complex detection. This can be explained by the weak association of MRN deficiency with type II EOC.

Conclusion
In conclusion, lack of protein detection of the MRN complex occurs more frequently in low-grade EOC and is associated with MMR deficiency. A potential role of MRN as a biomarker for therapies targeting cancers with BRCA1ness such as PARP inhibitors needs to be examined in clinical trials.

Acknowledgements
We thank Martina Storz and André Fletsche for excellent technical assistance.

Funding
This study was partially funded by the Zurich Cancer League (Zürcher Krebsliga).

Availability of data and material
The datasets analysed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
AN established and analysed IHC, performed the statistical analysis and drafted parts of the manuscript. KJD performed in vitro experiments and drafted parts of the manuscript. AKZ generated the TMA. HM and DF helped to draft the manuscript. EPS performed in vitro experiments and drafted parts of the manuscript. KJD interpreted the data, revised the manuscript, and conceived the study together with AN. All authors read and approved the manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
The study was approved by the local scientific ethics committee (KEK-ZH-Nr: 8091 Zurich, Switzerland. 3Kempf & Pfaltz, Histologische Diagnostik ag, Switzerland. 2Department of Gynecology, University Hospital Zurich, CH-8091 Zurich, Switzerland. 1Department of Gynecology, University Hospital Zurich, CH-8091 Zurich, Switzerland. 4Kempf & Pfaltz, Histologische Diagnostik ag, Zurich, Switzerland.

Received: 23 July 2015 Accepted: 20 December 2016
Published online: 10 January 2017

References
1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.
2. Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Archiv. 2012;460(3):237–49.
3. Romero I, Bart Jr RC. Minireview: human ovarian cancer: biology, current management, and paths to personalized therapy. Endocrinology. 2012;153(4):593–602.
4. Zhang S, Royer R, Li S, Mclaughlin JR, Rosen B, Risch HA, Fan I, Bradley L, Shaw PA, Narod SA. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol. 2011;121(2):353–7.
5. Alsop K, Fereday S, Meldrum C, DeFazio A, Emmanuel C, George J, Dobrovic A, Blirner MJ, Webb PM, Stewart C, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer. a report from the Australian Ovarian Cancer Study Group. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(21):2654–63.
6. Pennington KP, Walsh T, Harrel MI, Lee MK, Penni CL, Rendi MH, Thornton A, Norquist BM, Casadei S, Nord AS, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764–75.
7. Nagaraju G, Scully R. Minding the gap: the underground functions of BRCA1 and BRCA2 at stalled replication forks. DNA repair. 2007;6(7):1018–31.
8. Li GM. Mechanisms and functions of DNA mismatch repair. Cell Res. 2008;18(1):85–98.
9. Williams GJ, Lees-Miller SP, Tainer JA. Mre11-Rad50-Nbs1 conformations and the control of sensing, signaling, and effector responses at DNA double-strand breaks. DNA repair. 2010;9(12):299–306.
10. Bartkova J, Tommiska J, Oplutlova L, Aaltinen K, Tamminen A, Heikkinen T, Mitrakis A, Attomaki K, Blomqvist C, Heikkila P, et al. aberrations of the MRE11-RAD50-NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer-predisposing gene. Mol Oncol. 2008;2(4):296–316.
11. Ebi H, Matsuo K, Sugito N, Suzuki M, Osada H, Tajima K, Ueda R, Takahashi T, Nowoslawska A, Okazaki T. Novel NBS1 heterogeneous germ line mutation causing MRE11-binding domain loss predisposes to common types of cancer. Cancer Res. 2007;67(23):1158–65.
12. Heikkilä K, Karpinnen SM, Soini Y, Makinen M, Winquist R. Mutation screening of Mre11 complex genes: indication of RAD50 involvement in breast and ovarian cancer susceptibility. J Med Genet. 2003;40(12):e131.
13. Lu I, Wei Q, Bondy ML, Li D, Brewster A, Shete S, Yu TK, Sahin A, Menc-Bemstarn F, Hunt KK, et al. Polymorphisms and haplotypes of the NBS1 gene are associated with risk of sporadic breast cancer in non-Hispanic white women < or = 55 years. Carcinogenesis. 2006;27(11):2209–16.
14. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Oikarinen A, Loman N, et al. Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010;376(9737):245–51.
15. Banerjee S, Kaye S. PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond. Curr Oncol Rep. 2011;13(6):442–9.
16. Lynch HT, Casey MJ, Snyder CL, Brenton JD, and management. Mol Oncol. 2009;3(2):97–137.
17. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swisland H, Luu A, O’Connor MJ, et al. Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123–34.
18. Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, De Greve J, Lubinski J, Shanley S, Messiou C, et al. Poly(ADP-ribose)polymerase inhibitor olaparib in patients with platinum-sensitive relapsed ovarian cancer: a phase II trial. Lancet. 2014;383(9931):222–31.
19. Bartkova J, Tommiska J, Oplutlova L, Aaltinen K, Tamminen A, Heikkilä P, et al. Aberrations of the MRE11-RAD50-NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer-predisposing gene. Mol Oncol. 2008;2(4):296–316.
20. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15):1382–92.
21. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15(8):652–61.
22. Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609–15.
23. Dellas A, Puhl A, Schraml P, Thornke SE, Ruschhoff J, Mihatsch MJ, Mohr C. Molecular and clinicopathological analysis of ovarian carcinomas with and without microsatellite instability. Anticancer Res. 2004;24(1):361–9.
24. Xiao X, Melton DW, Gourley C. Mismatch repair deficiency in ovarian cancer – molecular characteristics and clinical implications. Gynecol Oncol. 2014;132(2):506–12.
25. Koppensteiner R, Samartzis EP, Nosike A, Von Teichman A, Dedes I, Gwerder M, Imesch P, Ilbenberg K, Mohr C, Fink D, et al. Effect of MRE11 loss on PARP inhibitor sensitivity in endometrial cancer in vitro. PLoS ONE. 2014;9(6), e100041.
25. Opstruplova L, Wolanin K, Mistrik M, Korinkova G, Simkova D, Bouchal J, Lenobel R, Bartkova J, Lau A, O’Connor MJ, et al. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment. Cell Cycle. 2012;11(20):3837–50.

26. Villar E, Bartnik CM, Sterzel SL, Raskin L, Ahn J, Moreno V, Mukherjee B, Iniesta MD, Morgan MA, Rennert G, et al. MRE11 deficiency increases sensitivity to poly (ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers. Cancer Res. 2011;71(7):2632–42.

27. Dedes KJ, Willkerson PM, Wetterskoog D, Weigelt B, Ashworth A, Reis-Filho JS. Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell Cycle. 2011;10(8):1192–9.

28. Liu JF, Konstantinopoulos PA, Matulonis UA. PARP inhibitors in ovarian cancer: Current status and future promise. Gynecol Oncol. 2014;133(2):362–9.

29. McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, Giavara S, Liu JF, Konstantinopoulos PA, Matulonis UA. PARP inhibitors in ovarian cancer: Current status and future promise. Gynecol Oncol. 2014;133(2):362–9.

30. Noske A, Zimmermann AK, Caduff R, Vaiku S, Giavara S, Trott A, Viel A, Fink D, Moch H, Kristiansen G. Alpha-methylacyl-CoA racemase (AMACR) expression in epithelial ovarian cancer. Virchows Archiv. 2011;459(1):101–7.

31. Robert J, Kurman MLC, Simon Herrington C, Young RH. WHO Classification of Tumours of Female Reproductive Organs. 4th ed. Lyon: IARC; 2014.

32. Kurman R, Shih le M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer; shifting the paradigm. Hum Pathol. 2011;42(7):918–31.

33. Dedes KJ, Wetterskoog D, Mendes-Pereira AM, Natrajan R, Lambros MB, Geyer FC, Vatcheva R, Savage K, Mackay A, Lord CJ, et al. PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci Transl Med. 2010;2(35):33ra75.

34. Hematulin A, Sagan D, Eckardt-Schupp F, Moertl S. NBS1 is required for IGF-1 induced cellular proliferation through the Ras/Raf/MEK/ERK cascade. Cell Signal. 2008;20(12):2276–85.

35. Rechsteiner M, Zimmermann AK, Wild PJ, Caduff R, Von Teichman A, Fink D, Moch H, Noske A. TP53 mutations are common in all subtypes of epithelial ovarian cancer; and we will help you at every step:

Submit your next manuscript to BioMed Central and we will help you at every step:
• We accept pre-submission inquiries
• Our selector tool helps you to find the most relevant journal
• We provide round the clock customer support
• Convenient online submission
• Thorough peer review
• Inclusion in PubMed and all major indexing services
• Maximum visibility for your research
Submit your manuscript at www.biomedcentral.com/submit